2025 eastern region candidates 

I was the Chair of the HUPO 2019 in Adelaide together with Prof Stuart Cordwell and have been Vice President of the Australasian Proteomics Society from 2012-2019 and I was the President of the Australasian Proteomics Society from 2020-2025. I have served as the Treasurer of the HUPO Executive Committee from 2017-2019 and 2021-2022. I'm the Vice President of HUPO in the moment. I have been a member of the HUPO Council since 2015 and served as a member of the Nomination Committee.

I have worked in Proteomics since 1999 and attended almost all HUPO conferences since 2005. My research focus on the application of Proteomics in cancer research and on I was the Chair of the HUPO 2019 in Adelaide together with Prof Stuart Cordwell and have been Vice President of the Australasian Proteomics Society from 2012-2019 and I'm now the President of the Australasian Proteomics Society. I have served as the Treasurer of the HUPO Executive Committee from 2017-2019. I have been a member of the HUPO Council since 2015 and served as a member of the Nomination Committee. I have worked in Proteomics since 1999 and attended almost all HUPO conferences since 2005. My research focus on the application of Proteomics in cancer research and on the use of Mass Spectrometry Imaging as diagnostic tool in cancer research.

In all my engagements with HUPO and in the multiple functions I have hold in the past I always pushed for a more a democratic process and for gender equality. Taking in consideration my previous tenure as treasurer and Vice President of the HUPO and as Chair of the very successful HUPO 2019 in Adelaide, I feel that I'm well suited to serve on the HUPO council again.

My doctoral training was in protein and peptide separation and the sensitive detection and characterization of peptides. In 1994, as a postdoc I began a fascination with immune recognition and the key role peptides play in modulating health and disease. After further postdoctoral studies I was awarded a CR Roper Fellowship in 2003 and began an independent research career in which I have applied cutting edge mass spectrometry to key questions in immunology.

In 2005 I moved to the Bio21 Institute as the Grimwade Research Fellow at University of Melbourne. In 2008 I was awarded an NHMRC Senior Research Fellowship and in 2009 appointed as a Reader. In July 2012 I was recruited back to Monash as a Professor and Head of Quantitative Proteomics. I am currently Deputy Head of the Department of Biochemistry at Monash University and Vice-President of the Australasian Proteomics Society. I am passionate about career development and mentoring early career researchers - especially in proteomics which is often complicated by the requirement for access to high end instrumentation and thus limited opportunities for ECRs.

I have been active in HUPO since 2010 regularly attending meetings and contributing to initiatives including the Human Immunopeptidome Project and the Human Proteome Project (on the SAB 2020-2023). My laboratory focuses on how the diverse array of peptides presented to the immune system, the immunopeptidome, is influenced by infection, inflammation and the environment. We have made important contributions to understanding the role of antigen presentation, including characterizing peptide epitopes involved in T cell recognition in autoimmunity, allergy, cancer and infectious diseases. I have been instrumental in bringing quantitative tools to immunological studies, in particular the use of multiple reaction monitoring to calculate epitope cell surface expression. My lab was one of the first to adopt new data independent acquisition techniques and apply it to quantitate antigen presentation at the protein and peptide epitope level as well as to understand complex host-pathogen interactions. The application of this technology in the clinic represents an new and exciting direction that falls under the umbrella of HUPO activities and interests.

As the Founder and CEO of Nanomics Biotech, my mission is to democratize large-scale proteomics by advancing proteome profiling technologies, high-throughput automation, and scalable standardized workflows. With an interdisciplinary academic foundation in Molecular Engineering from the University of Chicago and broad industrial engagement worldwide, I bring a unique perspective shaped by both frontier science and practical implementation across diverse research ecosystems.

At Nanomics, we’ve engineered automated platforms and proteome profiling methods that enhance reproducibility, sensitivity, and cost-efficiency in plasma and other proteomics. These tools are enabling clinical-scale applications for biomarker discovery and target validation. I’ve pioneered cross-sector collaborations through co-marketing strategies, including offering free equipment to facilitate adoption in resource-limited settings.

My work is anchored in global cooperation—partnering with top-tier institutions such as the University at Buffalo, Harvard Medical School, Pacific Northwest National Laboratory (PNNL), Bio21 Institute, and Ions Lab. These academic-industry alliances exemplify my commitment to translating research into impact through scalable, accessible platforms that benefit scientists and patients alike.

I strongly support HUPO’s mission to advance proteomics through inclusivity, cooperation, and translational value. If elected to Council, I aim to contribute to initiatives that strengthen academia-industry connections, promote technical standardization, and expand infrastructure for proteomics in emerging regions. I bring experience in communication strategy, academia-industry alignment, and workflow optimization—coupled with a deep commitment to collective progress across borders and sectors. Serving on HUPO Council would be a privilege and a strategic opportunity to elevate the democratization of proteomics through global collaboration and interdisciplinary integration.